Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Barbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 6/20 | 0.39 |
| ▸ | MMP8 | P22894 | 5/20 | 0.39 |
| ▸ | MMP2 | P08253 | 5/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Barbital SCHEMBL43818 | 0.88 | LMNA (1.00) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL4888618 | 0.86 | LMNA (0.77) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL11328256 | 0.85 | LMNA (0.94) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL236590 | 0.85 | LMNA (0.94) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL11212132 | 0.85 | LMNA (0.94) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL23533431 | 0.85 | LMNA (0.94) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL2128102 | 0.85 | LMNA (0.94) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL21084914 | 0.85 | LMNA (0.94) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL21084955 | 0.85 | LMNA (0.94) | LMNATP53ALDH1A1HSD17B10MMP9 | |
| Barbital SCHEMBL4525046 | 0.84 | LMNA (0.81) | LMNATP53ALDH1A1HSD17B10MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312297-A1 | REDUCTION OF HEALTHCARE RESOURCE UTILIZATION BY PATIENTS TREATED WITH INTRANASALLY-ADMINISTERED METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-10-09 | — | — | US | claimed |
| US-20250302777-A1 | METHODS FOR TREATING GASTROPARESIS | EVOKE PHARMA, INC. | 2025-10-02 | — | — | US | claimed |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-07-17 | — | — | US | claimed |
| US-12194008-B2 | Nasal formulations of metoclopramide | EVOKE PHARMA, INC. (US) | 2025-01-14 | — | — | US | claimed |
| US-12194009-B2 | Nasal formulations of metoclopramide | EVOKE PHARMA, INC. (US) | 2025-01-14 | — | — | US | claimed |
| WO-2024137814-A1 | REDUCTION OF HEALTHCARE RESOURCE UTILIZATION BY PATIENTS TREATED WITH INTRANASALLY-ADMINISTERED METOCLOPRAMIDE | EVOKE PHARMA, INC (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024137805-A1 | NOVEL METHODS FOR TREATING GASTROPARESIS | EVOKE PHARMA, INC (US) | 2024-06-27 | — | — | WO | claimed |
| US-11813231-B2 | Nasal formulations of metoclopramide | EVOKE PHARMA, INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20210338608-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2021-11-04 | — | — | US | claimed |
| US-20210330619-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2021-10-28 | — | — | US | claimed |
| EP-1385494-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS | Dey L.P. (US) | 2004-02-04 | — | — | EP | claimed |
| EP-1381346-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | Dey L.P. (US) | 2004-01-21 | — | — | EP | claimed |
| US-6667344-B2 | Bronchodilating compositions and methods | DEY, L.P. | 2003-12-23 | — | — | US | claimed |
| WO-2002083079-A9 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY L P (US) | 2003-04-10 | — | — | WO | claimed |
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | DEY L.P. | 2003-03-20 | — | — | US | claimed |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | MYLAN PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| WO-2002083079-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | DEY L.P. | 2002-10-17 | — | — | US | claimed |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338608-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | MC2R, MTNR1B, MC4R | LMNA 2480/4885TP53 4637/4885ALDH1A1 2584/4885 |
| US-20210330619-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | MC2R, MTNR1B, MC4R | LMNA 2480/4885TP53 4637/4885ALDH1A1 2584/4885 |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | LMNA 908/4885TP53 3971/4885ALDH1A1 2567/4885 |
| US-12194008-B2 | Nasal formulations of metoclopramide | MC2R, MTNR1B, MC4R | LMNA 2480/4885TP53 4637/4885ALDH1A1 2584/4885 |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | MC2R, MTNR1B, MC4R | LMNA 2480/4885TP53 4637/4885ALDH1A1 2584/4885 |
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | SERPINA6, CALU, TSLP | LMNA 1270/4885TP53 3849/4885ALDH1A1 2861/4885 |
| US-11813231-B2 | Nasal formulations of metoclopramide | MC2R, MTNR1B, MC4R | LMNA 2480/4885TP53 4637/4885ALDH1A1 2584/4885 |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | AREG, IL5, IL17A | LMNA 1095/4885TP53 3418/4885ALDH1A1 3372/4885 |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | LMNA 908/4885TP53 3971/4885ALDH1A1 2567/4885 |
| US-12194009-B2 | Nasal formulations of metoclopramide | MC2R, MTNR1B, MC4R | LMNA 2480/4885TP53 4637/4885ALDH1A1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.